/
Oncology
Neuroblastoma
85
Pipeline Programs↗
90
Active Trials↗
42
Companies Involved↗
Neuroblastoma is a moderately active landscape with 85 programs across 42 companies. The most active players are Princess Maxima Center for Pediatric Oncology, Ascentage Pharma Group Inc., Eli Lilly. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 119
Phase 234
Phase 322
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
55 of 77 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 99% of 85 pipeline programs.
Analysis
Trial Status
288
clinical trials
Completed122 · 42%
Recruiting51 · 18%
Active, not recruiting31 · 11%
Unknown status29 · 10%
Terminated28 · 10%
Withdrawn9 · 3%
Other18 · 6%
Clinical Trials
Trial Activity
288 trials
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Recruiting·—·Phase 2·NCT06540963·98 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)